H. pylori eradication should be surrogate in treatment of active/inactive duodenal ulcers -- Astra Merck.
HELICOBACTER PYLORI ERADICATION IN INACTIVE ULCERS SHOULD BE "SURROGATE" for prevention of duodenal ulcer relapse, Astra Merck Director of Gastrointestinal Clinical Research Garry Neil, MD, maintained at a Jan. 28 International Business Communications meeting on H. pylori in Washington, D.C. "We would suggest that cure of H. pylori infection can and should be regarded as a surrogate marker for prevention of duodenal ulcer disease irrespective of the presence of" an active crater "at the time of diagnosis," Neil said.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth